Nonsense, Board would never approve, with BTD and a favorable study in Type2 with Covid19, RVX value is 10 times what you suggest. Annual royalites would exceed your buy out. Take a real look, go back to the 2015 annual meeting, see last 25 minutes of 87 minute meeting. Yes I know, some say who knows what the study will bring, than you really do not understand how Apabetalone interacts with each cell. 13 years of testing live patients, this is a very safe drug with many benefits. The Board would reject the offer.